{
  "id": "monogenic-diabetes",
  "title": "Monogenic Diabetes",
  "lang": "en",
  "source_lang": "en",
  "summary": "Monogenic diabetes comprises uncommon forms of diabetes caused by changes in a single gene, with features and treatment responses that depend on the underlying genetic cause.",
  "category": "health",
  "subcategory": "diseases",
  "type": "concept",
  "aliases": [
    "Monogenic diabetes mellitus"
  ],
  "generated_at": "2026-11-04",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/monogenic-diabetes/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/monogenic-diabetes/",
      "json": "https://aiwiki.page/zh/monogenic-diabetes.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "Monogenic diabetes is a group of forms of diabetes mellitus caused primarily by a disease-causing alteration in a single gene. Most affect the development or function of insulin-producing cells, although some cause severe resistance to insulin. The principal clinical groups are maturity-onset diabetes of the young (MODY), neonatal diabetes, and diabetes occurring within broader genetic syndromes. Identifying the genetic cause can clarify inheritance, explain associated abnormalities, and substantially change treatment."
    },
    {
      "heading": "Biological basis and inheritance",
      "text": "In most monogenic forms, diabetes results from impaired insulin production or secretion by beta cells in the pancreatic islets. The affected genes may regulate pancreatic development, glucose sensing, electrical activity in beta cells, or insulin synthesis. Less commonly, a genetic defect impairs insulin action in other tissues, producing severe insulin resistance.\n\nThis differs from the usual mechanisms of type 1 diabetes, in which autoimmune destruction causes insulin deficiency, and type 2 diabetes, which generally reflects interactions among many genetic variants, environmental exposures, insulin resistance, and progressive beta-cell dysfunction. These distinctions are not absolute clinical boundaries: obesity, autoimmunity, or other metabolic conditions can coexist with a monogenic disorder.\n\nInheritance depends on the underlying cause:\n\n- Autosomal dominant inheritance: One altered gene copy can cause disease. Many common MODY subtypes follow this pattern, often producing diabetes across successive generations.\n- Autosomal recessive inheritance: Disease generally results from pathogenic variants in both copies of a gene. This occurs in several syndromic and neonatal forms.\n- Mitochondrial inheritance: Disease-causing mitochondrial DNA variants are transmitted through the maternal line.\n- De novo variants: A pathogenic variant may arise in an affected person without being present in either parent.\n\nConsequently, absence of a family history does not exclude monogenic diabetes. Age at onset and severity can also vary among relatives with the same variant."
    },
    {
      "heading": "Major clinical groups",
      "text": "Maturity-onset diabetes of the young\n\nMaturity-onset diabetes of the young traditionally describes familial, usually autosomal dominant diabetes caused by impaired beta-cell function. It commonly becomes apparent in childhood, adolescence, or early adulthood, but diagnosis at an older age is possible. The historical name does not mean that every affected person develops diabetes when young or has the same clinical course.\n\nImportant causes include:\n\nGenetic cause | Typical characteristics\nGCK | A higher glucose threshold for insulin secretion, usually causing mild, stable fasting hyperglycemia from birth\nHNF1A | Progressive impairment of insulin secretion, often with marked sensitivity to sulfonylureas\nHNF4A | Progressive beta-cell dysfunction; some affected individuals have a history of increased birth weight and neonatal hypoglycemia\nHNF1B | Diabetes associated with developmental abnormalities, particularly kidney and urinary tract abnormalities; pancreatic underdevelopment and genital tract abnormalities can also occur\n\nGene-based names are more informative than numbered MODY labels because they directly identify the biological cause. Not all genes historically described as MODY genes have equally strong evidence supporting a causal relationship.\n\nNeonatal diabetes\n\nNeonatal diabetes usually presents within the first six months of life. It may be permanent or transient; transient disease can remit during infancy and recur later. Diabetes at this age is particularly suggestive of a genetic cause because autoimmune type 1 diabetes is very uncommon in early infancy.\n\nImportant causes include pathogenic variants in KCNJ11, ABCC8, and INS. KCNJ11 and ABCC8 encode components of the ATP-sensitive potassium channel in beta cells. Certain activating variants prevent normal channel closure, disrupting the electrical signal that triggers insulin release.\n\nTransient neonatal diabetes can also result from abnormalities of the imprinted region at chromosome 6q24. These include mechanisms involving chromosome dosage or imprinting rather than a conventional single-gene sequence variant.\n\nSome neonatal forms involve other organs. Certain KCNJ11 variants, for example, are associated with developmental delay and epilepsy as well as diabetes.\n\nSyndromic and mitochondrial forms\n\nDiabetes can be one component of a broader inherited disorder. Examples include:\n\n- Wolfram syndrome, commonly associated with biallelic WFS1 variants and characterized by diabetes mellitus and optic atrophy, with other manifestations possible.\n- Maternally inherited diabetes and deafness, often associated with the mitochondrial DNA variant m.3243A&gt;G and sensorineural hearing loss.\n- Severe insulin-resistance syndromes, including disorders caused by pathogenic variants in the insulin receptor gene.\n- Genetic lipodystrophies, in which abnormal adipose tissue distribution contributes to severe insulin resistance.\n\nThese conditions are not necessarily classified as MODY, even when diabetes begins early."
    },
    {
      "heading": "Clinical recognition and diagnosis",
      "text": "Clinical features that can raise suspicion include very early onset, diabetes in successive generations, persistent insulin secretion despite an apparent diagnosis of type 1 diabetes, mild stable fasting hyperglycemia, or diabetes accompanied by characteristic kidney, auditory, neurological, or developmental abnormalities. None of these features alone establishes the diagnosis.\n\nThe assessment may combine:\n\n- Age at onset and detailed family history.\n- Measurements of glucose and glycated hemoglobin.\n- Tests for pancreatic islet autoantibodies.\n- C-peptide measurement to assess endogenous insulin secretion.\n- Evaluation of associated organ abnormalities.\n- Genetic testing appropriate to the suspected condition.\n\nNegative autoantibodies do not by themselves prove monogenic diabetes, and detectable C-peptide is not specific to it. Similarly, body weight alone cannot reliably distinguish monogenic diabetes from other types.\n\nMolecular testing may use a multigene panel, targeted analysis of a suspected gene, or broader sequencing. Depending on the phenotype, testing may also need to detect deletions, duplications, mitochondrial variants, or imprinting abnormalities that standard sequencing does not reliably identify.\n\nA variant of uncertain significance is not equivalent to a confirmed genetic diagnosis. Interpretation depends on the strength of the gene–disease relationship, the variant’s characteristics, the clinical findings, and sometimes its segregation within a family. Genetic counseling addresses inheritance, variable expression, and the implications of testing for relatives."
    },
    {
      "heading": "Treatment implications",
      "text": "Monogenic diabetes is an important example of precision medicine because treatment can depend directly on the molecular defect.\n\nMany people with GCK-related hyperglycemia have stable, mild glucose elevation and generally do not require glucose-lowering medication outside particular circumstances. Pregnancy is a distinct setting because fetal genotype and growth influence the interpretation and management of maternal hyperglycemia.\n\nPeople with HNF1A- or HNF4A-related diabetes often respond strongly to sulfonylureas, which stimulate insulin secretion. This sensitivity also creates a risk of hypoglycemia. Insulin may become necessary as beta-cell function declines.\n\nMany people with neonatal diabetes caused by suitable KCNJ11 or ABCC8 variants can achieve effective glucose control with sulfonylureas rather than insulin. This response is variant-dependent and does not apply to all neonatal diabetes. Other forms, including many caused by INS variants or substantial pancreatic developmental defects, commonly require insulin.\n\nThe genetic diagnosis can also identify a need to assess associated abnormalities, such as kidney disease in HNF1B-related disease. Treatment changes based on molecular findings require specialist assessment; a suggestive clinical pattern alone is not sufficient evidence for changing medication."
    },
    {
      "heading": "Prognosis and diagnostic limitations",
      "text": "Long-term outcomes vary considerably. GCK-related mild hyperglycemia generally carries a low risk of diabetes-related microvascular complications, whereas progressive forms can cause the complications associated with sustained hyperglycemia. In syndromic disease, neurological, renal, or other manifestations may substantially influence prognosis independently of glucose control.\n\nMonogenic diabetes is frequently misclassified as type 1 or type 2 diabetes. Its reported frequency depends on the population studied, selection criteria, and access to testing, so estimates from specialist cohorts do not necessarily represent the general population.\n\nA negative genetic test does not exclude every monogenic cause. Some relevant changes are difficult to detect, and not all disease-causing genes or mechanisms are known. Conversely, finding a rare genetic variant does not establish that it caused the diabetes; accurate diagnosis requires both reliable variant interpretation and a compatible clinical picture."
    }
  ],
  "links": [
    "diabetes-mellitus",
    "gene",
    "insulin",
    "pancreatic-islets",
    "insulin-resistance",
    "type-one-diabetes",
    "type-two-diabetes",
    "epilepsy",
    "hearing-loss",
    "glycated-hemoglobin",
    "precision-medicine",
    "pregnancy",
    "hypoglycemia",
    "hyperglycemia"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}